Imatinib Mesylate (Gleevec)
Busulfan (Myleran)
Dasatinib
These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.